Carol A Aghajanian

The Pan-tumor Landscape, Allelic Status, and Genomic Complexity of SMARCA4 Alterations

Matteo Repetto, Michael V. Gormally, Jason C. Chang, Pier Selenica et autres

PURPOSE: The clinical implications of distinct SMARCA4 alteration classes remain incompletely defined. We performed a pan-cancer analysis to characterize SMARCA4 mutation classes and their associations with allelic status, genomic context, and therapeutic outcomes. PATIENTS AND METHODS: We analyzed 68,920 tumor-normal paired samples …

us (code pays fourni par la source)

Supplementary Table S1 from A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number–High/p53-Abnormal Endometrial Cancer

Maria M Zlobinsky Rubinstein, Jennifer Y. Ge, Qin C Zhou, Alexia E. Iasonos et autres

Clinical characteristics and prior treatments of study participants.

Supplementary Table S2 from A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number–High/p53-Abnormal Endometrial Cancer

Maria M Zlobinsky Rubinstein, Jennifer Y. Ge, Qin C Zhou, Alexia E. Iasonos et autres

Representativeness of study participants.

Data from A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number–High/p53-Abnormal Endometrial Cancer

Maria M Zlobinsky Rubinstein, Jennifer Y. Ge, Qin C Zhou, Alexia E. Iasonos et autres

AbstractPurpose: Copy number–high (CN-H)/p53-abnormal endometrial cancers are high-grade uterine malignancies characterized by TP53 mutations, copy-number alterations, mismatch repair proficiency (MMRp), and absence of POLE mutations. A subset may be homologous recombination deficient (HRD), potentially conferring sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors. …

Supplementary Figure S1 from A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number–High/p53-Abnormal Endometrial Cancer

Maria M Zlobinsky Rubinstein, Jennifer Y. Ge, Qin C Zhou, Alexia E. Iasonos et autres

Exploratory analysis of the three components of the HRD score.

Supplementary Figure S2 from A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number–High/p53-Abnormal Endometrial Cancer

Maria M Zlobinsky Rubinstein, Jennifer Y. Ge, Qin C Zhou, Alexia E. Iasonos et autres

Comparison of HRD scores in primary vs. recurrent disease and untreated vs. previously treated disease.

Prognostic comparison of the FIGO 2009 and 2023 endometrial cancer staging systems: a large, single-institution retrospective cohort study

Tiffany Sia, Qin C Zhou, Sean Devlin, Alexia Iasonos et autres

Objective The International Federation of Gynecology and Obstetrics (FIGO) 2023 endometrial cancer staging system includes 21 substages and proposes a shift from pure anatomic staging to an approach incorporating histology, grade, lymphovascular invasion, and molecular classification. We sought to evaluate the overall …

us (code pays fourni par la source)

Long-term efficacy and safety of avutometinib + defactinib in patients with recurrent low-grade serous ovarian cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201

Rachel Grisham, Els Van Nieuwenhuysen, Alessandro Santin, Véronique D'Hondt et autres

us, be, fr, gb, es, it (code pays fourni par la source)

A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor

Elizabeth E. Hopp, Danielle M. Enserro, Susana Campos, Viola Chitiyo et autres

us (code pays fourni par la source)

Phase III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial carcinoma (NRG-GY026)

Britt Erickson, Danielle M. Enserro, Healther Lankes, Lauren Dockery et autres

us (code pays fourni par la source)

Molecular sub group and post immunotherapy analysis: Results from NRG GY012

Helen MacKay, B.J. Rimel, David Bender, Shannon Westin et autres

ca, us (code pays fourni par la source)

Age at ovarian cancer diagnosis varies by lynch syndrome gene: A genetic testing laboratory registry study

Ying Liu, Christina E. Curtin, Alicia J. Latham, Kelsey E. Breen et autres

us (code pays fourni par la source)